Macular hole formation following intravitreal injection of ranibizumab for branch retinal vein occlusion: a case report.

Abstract

BACKGROUND:

Macular hole formation after anti-vascular endothelial growth factor therapy is a rare complication. We report macular hole formation after intravitreal ranibizumab injection for branch retinal vein occlusion.

CASE PRESENTATION:

A 63-year-old Asian male was treated with intravitreal ranibizumab injection for chronic macular edema with branch retinal vein occlusion in his right eye. Before treatment, best-corrected visual acuity in his right eye was 20/200. Nine days after injection, a full thickness macular hole developed with reduction of macular edema. After pars plana vitrectomy combined with cataract surgery, the macular hole was successfully closed, and the best-corrected visual acuity in his right eye improved to 20/40.

CONCLUSION:

The possibility of an infrequent complication like macular hole should be considered for intravitreal ranibizumab for macular edema with branch retinal vein occlusion.

• Authors: Daisuke Muramatsu, Ryosuke Mitsuhashi, Takuya Iwasaki, Hiroshi Goto, Masahiro Miura
• Journal: BMC research notes (BMC Res Notes) Vol. 8 Pg. 358 (Aug 19 2015) ISSN: 1756-0500 [Electronic] England
• PMID: 26285577 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Vascular Endothelial Growth Factor A
• Ranibizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Gene Expression
• Humans
• Intravitreal Injections (adverse effects)
• Macular Edema (etiology, pathology, surgery)
• Male
• Middle Aged
• Ranibizumab (therapeutic use)
• Retinal Perforations (etiology, pathology, surgery)
• Retinal Vein (pathology, surgery)
• Retinal Vein Occlusion (pathology, surgery)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors, genetics, metabolism)